mohammed reda

mohammed reda


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MRmohammed reda
mohammed reda
YEYasmine ElHamadi
Yasmine ElHamadi
Cloning-vector performance emerges from the interaction of DNA cargo, vector architecture, host physiology and the intended experimental task. This narrative Review compares major bacterial and yeast cloning systems, including plasmids, bacteriophage-derived vectors, cosmids, phagemids, fosmids, bacterial and P1-derived artificial chromosomes, yeast plasmid families, yeast artificial chromosomes and shuttle platforms; mammalian chromosome-scale systems are considered as a focused extension. Rather than ranking vectors by nominal insert capacity, this Review examines cargo accommodation, replication, copy-number control, structural integrity, segregation, host compatibility, burden and workflow requirements. Particular attention is given to the distinct maintenance logic of Saccharomyces cerevisiae YEp, YCp and YIp vectors and to emerging episomal and chromosome-based systems in Komagataella phaffii. This Review proposes a revised Vector Performance and Design Framework (VPDF) that separates non-negotiable requirements from preferred performance targets, evaluates vector–host–cargo combinations across independent dimensions, and grades the evidence supporting each judgement. Worked examples show how the framework can structure decisions; they are not independent validation. It also sets out practical quality-assurance requirements: sequence-level verification, copy-number measurement and longitudinal assessment of clone retention. Drawing on both historical foundations and recent experimental evidence, this Review argues that vector choice is a context-specific engineering decision, not a capacity-based lookup.

16 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MRmohammed reda
mohammed reda
Background and objective: Gene-edited stem-cell products can address the causal biology of selected monogenic disorders, but their benefit depends on more than the proportion of alleles edited. The edited cells must retain self-renewal or tissue function, produce the intended phenotype, and remain genomically stable after administration. This review examines the evidence on gene-edited hematopoietic stem and progenitor cells (HSPCs), induced pluripotent stem cells (iPSCs), and their derivatives, focusing on editing precision, cellular fitness, potency, manufacturing, and long-term risk. Methods: This narrative review synthesizes mechanistic, preclinical, clinical, manufacturing, and regulatory literature, with emphasis on 2022 to November 2026 and on earlier pivotal work where needed. Evidence is organized thematically without a registered protocol or meta-analysis; clinical findings are distinguished from preclinical findings, and regulatory documents are interpreted according to jurisdiction and legal status. Key findings: Autologous ex vivo CRISPR-Cas9-edited CD34+ HSPCs provide the most mature clinical proof of concept, in sickle-cell disease and transfusion-dependent β-thalassemia. Base and prime editing widen the range of addressable variants and avoid a programmed double-strand break, but do not remove genotoxicity or delivery constraints. Translation is determined by on-target structural variation, off-target editing, DNA-damage responses, stem-cell fitness, clonal selection, conditioning toxicity, potency-assay relevance, manufacturing variability, and long-term surveillance. Conclusions: The translational objective is a genetically characterized, biologically competent, functionally potent, and acceptably safe cell product, not maximal editing efficiency in isolation. A product-centred strategy should link variant-level editing outcomes to cellular phenotype, durable engraftment or tissue function, clinical benefit, and proportionate long-term risk management.

9 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MRmohammed reda
mohammed reda
YEYasmine Elhamadi
Yasmine Elhamadi
Introns were historically defined by their removal from precursor messenger RNA during splicing. That definition remains accurate but does not capture the range of consequences associated with intron sequence, position, recognition, retention, excision and processing. Across plants, fungi, nematodes and mammals, introns can influence gene output at transcriptional, RNA-processing, export, stability and translational levels; some intronic DNA also acts as conventional cis-regulatory sequence, while some excised introns generate persistent regulatory RNAs. These phenomena are related but are not mechanistically interchangeable. This critical narrative review organizes them through a proposed Intron Regulatory State (IRS) framework that distinguishes genomic DNA, nascent RNA, spliceosome-engaged pre-mRNA, excised introns and intron-derived products. The evidence includes a human-cell massively parallel reporter assay using tens of thousands of synthetic introns, controlled positional tests in Caenorhabditis elegans, endogenous yeast intron deletions with multi-layer readouts, and genome-scale perturbation of conserved human intronic regions. The combined literature supports a bounded conclusion: intron-associated architecture can causally affect gene expression through more than one molecular layer, but the dominant route is context-dependent and cannot be inferred from a single endpoint. We therefore propose a causal experimental design using matched architectures, validated splice-competence controls, sequence-preserving perturbations, positional tests, multi-layer readouts and endogenous validation. IRS is presented as a hypothesis-generating analytical framework, not a validated scoring instrument or a universal model of intron function.

15 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MRmohammed reda
mohammed reda
Tumor metabolism has evolved from a feature of cancer cells to a potential therapeutic target. Cancer cells have to remodel their glucose, amino acid, lipid, nucleotide, mitochondrial and redox metabolism to meet their growth and survival needs. However, cancer metabolism is not static. Cancer cells are constantly redistributing metabolic fluxes in response to various stimuli. The metabolic flexibility of cancer cells poses an obstacle to metabolic therapy but also presents an opportunity to exploit their vulnerabilities. In this review article, we introduce the Metabolic Vulnerability-Adaptation Framework that explains how the metabolic rewiring of cancer cells creates dependencies that can be targeted by environmental and therapeutic stress. As a result, cancer cells adapt to these stresses, which shapes the outcome of treatment. We examine the metabolism of glucose and lactate, glutamine and amino acids, mitochondria, lipids and fatty acids, one-carbon and nucleotides, oncometabolites and redox homeostasis. A special focus is given to the competitive nature of cancer metabolism in the tumor microenvironment, immune cell metabolic dysfunction, the adaptation of cancer metabolism to therapy and the role of ferroptosis as a therapeutic endpoint. Also, we discuss various techniques to identify clinically relevant cancer metabolic states, such as biomarkers, stable-isotope tracing, metabolomics, spatial technologies, single-cell techniques, organoid models and multimodal profiling. Lastly, the future of cancer metabolism therapy is unlikely to be dominated by single metabolic pathway inhibitors. Instead, precision therapies will have to target specific cancer metabolic states to avoid cancer cells adapting to those therapies and suppressing the body's anti-cancer immune response.

18 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MRmohammed reda
mohammed reda
YEYasmine Elhamadi
Yasmine Elhamadi
Liver fibrosis is not just an issue of excessive extracellular-matrix deposition, but it is an outcome of the inability of the damaged liver to shift from injury repair to tissue homeostasis. Injured hepatocytes, inflammatory signaling, HSC activation, sinusoidal damage, and extracellular-matrix remodeling progressively transform the regenerative niche into an auto-perpetuating fibrotic niche. Stem-cell therapies need therefore to be assessed for their potential to reverse such an adverse microenvironment rather than for the replacement of hepatocytes only. A growing body of data supports that mesenchymal stromal cells (MSCs) modulate the phenotype of HSCs, macrophages, hepatocytes, endothelial cells, and the extracellular matrix via paracrine, extracellular vesicles, metabolic, and immune-mediated pathways. Among the mechanisms described are modulation of YAP/LOXL2 and TGF-β signaling, ferroptosis, autophagy, Hedgehog signaling, macrophage polarization, and intercellular RNA transfer. The clinical data are promising regarding safety and short-term gains in terms of liver-function tests but there is still a lack of proof of disease modification. In this Review, we present a liver-centric approach in which the criteria of success are the resolution of fibrosis and the recovery of regenerative competence rather than a biochemical benefit.

21 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MRmohammed reda
mohammed reda
YEYasmine Elhamadi
Yasmine Elhamadi
NMNehad Mahgoub Mabrouk
Nehad Mahgoub Mabrouk
MAMariam Ahmed
Mariam Ahmed
Introduction: Heart failure continues to be a significant source of morbidity and mortality despite advances in pharmacological therapies, devices, and mechanical circulatory support. Myocardial attrition, myocardial fibrosis, vascular dysfunction, inflammation, and ventricular remodeling represent a biological substrate that is not reversible with standard medical therapy and provide a rationale for regenerative approaches. Purpose: To examine the way in which potential mechanisms of action vary between stem cell-based technologies used in heart failure and to assess how cell type, disease state, administration route, dosage, outcomes selected, and safety impact the transition from laboratory science to clinical benefit. Method: Narrative review focused on mechanisms with searches of PubMed/MEDLINE and Google Scholar databases from inception to 31 August 2026 supplemented by screening of references from relevant reviews and primary papers. Synthesis of evidence was qualitative and organized by cellular platform and mechanism; no risk-of-bias scores were assigned nor pooled effect estimates produced. The final body of evidence included 81 papers, of which 11 were relevant clinical trials quantitatively summarized. Main body: Therapies based on adult stromal or progenitor cells have demonstrated poor engraftment with cardiomyocytes in the long term, which redirected efforts to explore the possible paracrine, angiogenic, immunomodulatory, and anti-fibrotic roles of such therapies. In contrast, pluripotent stem cell-derived cardiomyocytes represent a strategy for myocardial remuscularization. However, in this case, a significant number of issues arise regarding maturation, electrical coupling, arrhythmogenicity, immune compatibility, manufacturing, delivery, and safety over the long term. This review provides a critical evaluation of these two different therapeutic platforms along with their mechanisms, preclinical and clinical data, and translation obstacles. Conclusion: According to the data gathered thus far, there is no universal cell therapy for heart failure. Adult stromal and similar products act through mainly paracrine, vascular, immunomodulatory, and antifibrotic mechanisms, while pluripotent stem cell-derived cardiomyocytes are considered for myocardial remuscularization. In all cases, translation of biological effect into clinical efficacy depends on matching mechanism, proper patient selection, product characteristics, dosage, delivery, and safety over time. Therefore, future research should be aimed at distinction between preservation, repair, and regeneration, and biological hypotheses should correspond to clinical endpoints.